Malignant thymoma: current status of classification and multimodality treatment

Classification, understanding of the pathophysiology, and treatment options of thymoma have changed during recent years. It is hoped that novel strategies will lead to a survival benefit in these patients. It has become clear that patients with thymoma are best treated with multimodality therapy. In...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2003-02, Vol.82 (2), p.69-76
Hauptverfasser:	SCHMIDT-WOLF, I. G. H, ROCKSTROH, J. K, SCHÜLLER, H, HIRNER, A, GROHE, C, MÜLLER-HERMELINK, H. K, HUHN, D
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Clinical Trials as Topic Combined Modality Therapy Hematologic and hematopoietic diseases Humans Medical sciences Neoplasm Staging Other diseases. Hematologic involvement in other diseases Survival Rate Thymoma - classification Thymoma - pathology Thymoma - therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Classification, understanding of the pathophysiology, and treatment options of thymoma have changed during recent years. It is hoped that novel strategies will lead to a survival benefit in these patients. It has become clear that patients with thymoma are best treated with multimodality therapy. In this review, a pathologist, an immunologist, a surgeon, a radiotherapist, a pneumologist, and oncologists discuss the current status of classification and strategies for the treatment of patients with thymoma.
ISSN:	0939-5555 1432-0584
DOI:	10.1007/s00277-002-0597-6